<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 5 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:"Trebuchet MS";
panose-1:2 11 6 3 2 2 2 2 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
span.DefaultFontHxMailStyle
{mso-style-name:"Default Font HxMail Style";
font-family:"Arial",sans-serif;
color:windowtext;
font-weight:normal;
font-style:normal;
text-decoration:none none;}
span.org
{mso-style-name:org;}
span.locality
{mso-style-name:locality;}
span.region
{mso-style-name:region;}
span.postal-code
{mso-style-name:postal-code;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style></head><body lang=EN-CA link=blue vlink="#954F72" style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span class=DefaultFontHxMailStyle>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>See below for a raft of articles relating to some aspect of PCa.<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>Peruse at your leisure.<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>Thx.<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle>Glen<o:p></o:p></span></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><p class=MsoNormal>Sent from <a href="https://go.microsoft.com/fwlink/?LinkId=550986">Mail</a> for Windows</p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><div style='mso-element:para-border-div;border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal style='border:none;padding:0cm'><b>From: </b><a href="mailto:prostatepedia@naspcc.org">Prostatepedia</a><br><b>Sent: </b>June 10, 2022 11:02 AM<br><b>To: </b><a href="mailto:glen46nor@gmail.com">glen46nor@gmail.com</a><br><b>Subject: </b>Prostatepedia Digest Jun 10</p></div><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:#FAFAFA;border-collapse:collapse'><tr><td width="100%" valign=top style='width:100.0%;padding:7.5pt 7.5pt 7.5pt 7.5pt'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:450.0pt;border-collapse:collapse'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse'><tr><td valign=top style='background:#FAFAFA;padding:6.75pt 0cm 6.75pt 0cm'></td></tr><tr><td valign=top style='background:white;padding:6.75pt 0cm 0cm 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateHeader><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=2ad2e984f2&e=d1cc1ed898"><strong><span style='font-size:18.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:red'>Sign up for Prostatepedia's Free Publications</span></strong></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></td></tr><tr><td valign=top style='border:none;border-bottom:solid #EAEAEA 1.5pt;background:white;padding:0cm 0cm 6.75pt 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateBody><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><img border=0 width=564 height=162 style='width:5.875in;height:1.6875in' id="_x0000_i1031" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/d701134e-9eff-4181-a839-0b935f4b3420.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:13.5pt 13.5pt 13.5pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EAEAEA 4.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=d112a271ff&e=d1cc1ed898" title=""" "><span style='text-decoration:none'><img border=0 width=564 height=121 style='width:5.875in;height:1.2604in' id="_x0000_i1030" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/c8663230-e624-1404-57ee-513a4edbaecc.png"></span></a><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:13.5pt 13.5pt 13.5pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EAEAEA 1.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal style='line-height:150%'><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>Curated by Merel Nissenberg, President, NASPCC<br><br>*NASPCC publishes both PROSTATEPEDIA Magazine and the weekly PROSTATEPEDIA DIGEST* </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><strong><span style='font-size:24.0pt;line-height:150%;font-family:"Trebuchet MS",sans-serif;color:#202020'>New Links and Resources.</span></strong><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=8fac22b00d&e=d1cc1ed898"><span style='color:#007C89'>Prostatepedia's January/February on Radiation Therapy</span></a> </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'> <br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=ca2026db2f&e=d1cc1ed898"><span style='color:#007C89'>Prostatepedia’s Supplement Issue on Theranostics</span></a></span><span lang=EN-US style='font-size:12.0pt;line-height:150%;color:#202020;mso-fareast-language:EN-US'> </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>Risk of Venous Thromboembolism in Men With and Without Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=b1dfa08d03&e=d1cc1ed898"><span style='color:#007C89'>Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden.</span></a><br> <br>Importance of Regular Imaging in Men Receiving Potent Anti-Androgens in mHSPC: ARCHES Trial: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=9b17313ad3&e=d1cc1ed898"><span style='color:#007C89'>ARCHES Analysis Underscores Importance of Regular Imaging to Detect Progression in Patients With mHSPC Receiving Potent AR Inhibitors</span></a><br> <br>Patient Adherence Is Better with Enzalutamide than Abiraterone in Advanced Prostate Cancer, but with Cognitive Effects: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=bc73e509a1&e=d1cc1ed898"><span style='color:#007C89'>Patient Adherence Higher With Enzalutamide Than Abiraterone in Advanced Prostate Cancer but Cognitive Screening Suggested</span></a><br> <br>Synergy Between mpMRI and the PHI Test in Predicting Clinically Significant Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=5c4c6ab516&e=d1cc1ed898"><span style='color:#007C89'>A Combinatorial Neural Network Analysis Reveals a Synergistic Behaviour of Multiparametric Magnetic Resonance and Prostate Health Index in the Identification of Clinically Significant Prostate Cancer.</span></a><br> <br>Risk of Prostate Cancer in Veterans Who Have Rheumatoid Arthritis: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=dc06bde17d&e=d1cc1ed898"><span style='color:#007C89'>Risk of Prostate Cancer in U.S. Veterans with Rheumatoid Arthritis.</span></a><br> <br>New Combined Nomogram for Predicting Disease Progression Related to Castration Resistance: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=44b4c7d7b7&e=d1cc1ed898"><span style='color:#007C89'>Establishment of a Novel Combined Nomogram for Predicting the Risk of Progression Related to Castration Resistance in Patients With Prostate Cancer.</span></a><br> <br>Prognostic Factors for Survival and Ambulation with Spinal Cord Compression in Metastatic Disease: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=7b35e9fb58&e=d1cc1ed898"><span style='color:#007C89'>Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial.</span></a><br> <br>Validation of the DECIPHER Genomic Test in Patients Receiving Salvage Radiotherapy Without Hormone Therapy After Radical Prostatectomy: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=f11eb684f3&e=d1cc1ed898"><span style='color:#007C89'>Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy – An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial</span></a><br> <br>Health-Related Quality of Life in Localized Disease: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=8fe2ee89fe&e=d1cc1ed898"><span style='color:#007C89'>Patient reported outcomes and health related quality of life in localized prostate cancer: A review of current evidence.</span></a><br> <br>After Prostatectomy, Intensifying Salvage Treatment May Reduce Risk of Disease Progression: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=8a71605e23&e=d1cc1ed898"><span style='color:#007C89'>Intensifying Salvage Treatment Reduces Risk of Prostate Cancer Progression</span></a><br> <br>Overview of AUA 2022 from Europa Uomo: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=a23620acc1&e=d1cc1ed898"><span style='color:#007C89'>Highlights and vital PCa findings at AUA 2022</span></a><br> <br>Sleep Disturbances in Prostate Cancer Patients: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=400ecae29a&e=d1cc1ed898"><span style='color:#007C89'>Evaluating Patterns and Factors Related to Sleep Disturbances in Prostate Cancer Patients.</span></a><br> <br>Secondary Treatment for Men with Localized Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=dff7845496&e=d1cc1ed898"><span style='color:#007C89'>Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform.</span></a><br> <br>Efficacy and Safety of Relugolix versus Degarelix in Advanced Prostate Cancer Patients in Clinical Trials: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=f2ec724811&e=d1cc1ed898"><span style='color:#007C89'> The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.</span></a><br> <br>The Impact of BoneRx for Men With Prostate Cancer About to Start ADT: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=6e83950d45&e=d1cc1ed898"><span style='color:#007C89'>Implementing and Evaluating the Impact of BoneRx: A Healthy Bone Prescription for Men with Prostate Cancer Initiating Androgen Deprivation Therapy.</span></a><br> <br>New Therapy Options in Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=0fdacb3999&e=d1cc1ed898"><span style='color:#007C89'>Expanding Novel Therapy Options for Prostate Cancer Patients</span></a><br> <br>Pylarify Superior to Conventional Imaging in Unfavorable Intermediate or High-Risk Patients: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=e5af1da5c6&e=d1cc1ed898"><span style='color:#007C89'>Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer</span></a><br> <br> <br>Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer: ARASENS Trial; Plain Language Summary: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=bd0af03b96&e=d1cc1ed898"><span style='color:#007C89'>Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial</span></a><br> <br>Use of a Nanoparticle plus Enzalutamide for Treatment: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=79a3b1233e&e=d1cc1ed898"><span style='color:#007C89'>A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide.</span></a><br> <br>Statin and Metformin Use: AFFIRM, PREVAIL and PROSPER Trials: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=6fee7f15d8&e=d1cc1ed898"><span style='color:#007C89'>Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.</span></a><br> <br>Men with Prostate Cancer Have an Increased Risk of Venous Thromboembolism for 5 Years After Diagnosis: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=7f37338600&e=d1cc1ed898"><span style='color:#007C89'>Risk for VTE Up During 5 Years After Prostate Cancer Diagnosis</span></a><br> <br>ASCO 2022: Salvage Treatment After Radical Prostatectomy: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=e79af69bfc&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2022: Salvage Treatment for Biochemical Recurrence After Radical Prostatectomy</span></a><br> <br>ASCO 2022: Molecular-Based Imaging: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=f8ea7382ac&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2022: Molecular-Based Imaging Redefining the Disease Landscape</span></a><br> <br>ASCO 2022: Timing and Intensity of ADT in Biochemical Recurrence: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=785c82040f&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2022: Reimaging the Timing and Intensity of ADT in Biochemical Recurrence</span></a><br> <br>Lutetium and Cabazitaxel Have Similar Survival Outcomes in Men With mCRPC Who Have Progressed on Docetaxel: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=815aac6526&e=d1cc1ed898"><span style='color:#007C89'>177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel</span></a><br> <br>ASCO 2022: Looking for Intermediate Clinical Endpoints as Surrogates for Survival in Metastatic Hormone-Sensitive Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=55cf807d40&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2022: Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).</span></a><br> <br>ASCO 2022: A Substudy of the VISION Trial on Gallium 68 Baseline Imaging: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=bcc6625b2f&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2022: [68Ga]Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for Clinical Outcomes to [177Lu]Lu-PSMA-617 in Patients With mCRPC: A VISION Substudy</span></a><br> <br>ASCO 2022: Updating the THERA-P Trial with Dr. Michael Hoffmann on Lutetium versus Cabazitaxel in Metastatic CRPC: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=df7954fe33&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)</span></a><br> <br>ASCO 2022: Updated Overall Survival Outcomes in ENZAMET: Enzalutamide in Metastatic Hormone-Sensitive Disease: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=5fe03c7957&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2022: Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)</span></a><br> <br>ASCO 2022: The Busy Landscape in Hormone-Sensitive Prostate Cancer: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=3af47afad0&e=d1cc1ed898"><span style='color:#007C89'>ASCO 2022: Making Sense of the Intensified mHSPC Landscape - Discussion</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br> </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal style='line-height:150%'><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br></span><strong><span style='font-size:24.0pt;line-height:150%;font-family:"Trebuchet MS",sans-serif;color:#202020'>Reminders.</span></strong><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=071e53d0b2&e=d1cc1ed898"><span style='color:#007C89'>The 3RD Annual CPCC/UCSF Patient Conference On Prostate Cancer: “Using Current And Cutting-Edge Information To Help Make Informed Decisions” </span></a>October 15, 2022. This conference is for Patients, Family, Caregivers, and others.<br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:black'>On June 1, 2022, NASPCC President Merel Nissenberg and our PROSTATEPEDIA Editor Jessica Myers-Schecter interviewed NBA Hall-of-Famer Grant Hill on his new projects in communities concentrating on the awareness and early detection of prostate cancer. Grant Hill's interview will appear in the June issue of PROSTATEPEDIA Magazine on "TESTING"</span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>The 16<sup>th</sup> Annual Meeting of the National Alliance of State Prostate Cancer Coalitions (NASPCC) took place on January 28-30, 2022 in Washington, DC. A recording will be available soon.<br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:black'>The 17<sup>th</sup> Annual Meeting is scheduled to take place October 21-23, 2022 in Washington, DC. Details will be forthcoming</span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Arial",sans-serif;color:#202020'>Special PSMA Presentation with Dr. Michael Hofman from Melbourne, Australia: <a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=fd8ac0feb2&e=d1cc1ed898"><span style='color:#007C89'>https://prosticpreceptorship2022.org/program/session8/</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=c74ec7658c&e=d1cc1ed898"><span style='color:#007C89'>Merel Grey, president of NASPCC and Cal Ripken, Jr. Talk Prostate Cancer</span></a> <br><br><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=bd6de17454&e=d1cc1ed898"><span style='color:#007C89'>Jessie Myers-Schecter talks about her father, Snuffy Myers, and what it was like to be the daughter of a prostate cancer patient. </span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=bc8eb3255b&e=d1cc1ed898"><span style='color:#007C89'>NASPCC and CancerCare Online Prostate Cancer Patient Support Group</span></a><br><br><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=bf598cf9e2&e=d1cc1ed898"><span style='color:#007C89'>NASPCC Webinar Recordings Archive</span></a></span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><br><br></span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'> *****Patients who have had </span><span style='font-size:13.5pt;line-height:150%;color:#333333'>Genetics, Genomics + Prostate Cancer</span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'> or </span><span style='font-size:13.5pt;line-height:150%;color:#333333'>Chemotherapy and/or Immunotherapy</span><span style='font-size:13.5pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'>: we would like to interview you for the upcoming PROSTATEPEDIA Magazine!! Please contact <a href="mailto:mgrey@health.ucsd.edu"><span style='color:#007C89'>mgrey@health.ucsd.edu</span></a>*****</span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'> </span><span style='font-size:12.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#202020'><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><img border=0 width=564 height=436 style='width:5.875in;height:4.5416in' id="_x0000_i1029" src="https://mcusercontent.com/9154133f2e98aca1db87520cb/images/53731a5c-5b34-46de-a306-157337f67b36.jpg"><o:p></o:p></p></td></tr></table></td></tr></table></td></tr><tr><td valign=top style='background:#FAFAFA;padding:6.75pt 0cm 6.75pt 0cm;background:cover;-webkit-text-size-adjust:100%;background-size:cover;background-position-x:50%;background-position-y:50%' id=templateFooter><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 6.75pt 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:0cm 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 6.75pt 0cm 6.75pt;min-width:100%;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 7.5pt 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=a4a349bef0&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1028" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-twitter-48.png" alt=Twitter></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 7.5pt 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=297ba9682d&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1027" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-facebook-48.png" alt=Facebook></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td><td valign=top style='padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left style='border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:0cm 0cm 6.75pt 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td style='padding:3.75pt 7.5pt 3.75pt 6.75pt;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width=0 style='width:0cm;border-collapse:collapse;-webkit-text-size-adjust:100%'><tr><td width=24 style='width:18.0pt;padding:0cm 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><p class=MsoNormal align=center style='text-align:center'><a href="https://naspcc.us17.list-manage.com/track/click?u=9154133f2e98aca1db87520cb&id=b12e4e6d18&e=d1cc1ed898"><span style='text-decoration:none'><img border=0 width=24 height=24 style='width:.25in;height:.25in' id="_x0000_i1026" src="https://cdn-images.mailchimp.com/icons/social-block-v2/color-link-48.png" alt=Website></span></a><o:p></o:p></p></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table></div></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%;table-layout:fixed!important'><tr><td style='padding:7.5pt 13.5pt 18.75pt 13.5pt;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;border:none;min-width:100%;-webkit-text-size-adjust:100%'><tr><td style='border:none;border-top:solid #EEEEEE 1.5pt;padding:0cm 0cm 0cm 0cm;min-width:100%;-webkit-text-size-adjust:100%'></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;border-collapse:collapse;min-width:100%;-webkit-text-size-adjust:100%'><tr><td valign=top style='padding:6.75pt 0cm 0cm 0cm;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;margin-left:-2.25pt;margin-right:-2.25pt;-webkit-text-size-adjust:100%'><tr><td width=600 valign=top style='width:450.0pt;padding:0cm 0cm 0cm 0cm;max-width:100%;min-width:100%;-webkit-text-size-adjust:100%'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left width="100%" style='width:100.0%;border-collapse:collapse;-webkit-text-size-adjust:100%;word-break:break-word'><tr><td valign=top style='padding:0cm 13.5pt 6.75pt 13.5pt'><p class=MsoNormal align=center style='text-align:center;line-height:150%'><em><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Copyright © 2022 Prostatepedia NASPCC, All rights reserved.</span></em><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'> <br>You are receiving this email because you opted in via our website. <br><br><strong><span style='font-family:"Helvetica",sans-serif'>Our mailing address is:</span></strong> </span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><o:p></o:p></span></p><div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span class=org><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Prostatepedia NASPCC</span></span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><o:p></o:p></span></p><div><div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>1999 Avenue of the Stars Ste 1100<o:p></o:p></span></p></div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span class=locality><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>Los Angeles</span></span><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'>, <span class=region>CA</span> <span class=postal-code>90067-4618</span><o:p></o:p></span></p></div><p class=MsoNormal align=center style='text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><br><a href="https://naspcc.us17.list-manage.com/vcard?u=9154133f2e98aca1db87520cb&id=c67ed256e6"><span style='color:#656565'>Add us to your address book</span></a><o:p></o:p></span></p></div><p class=MsoNormal align=center style='margin-bottom:12.0pt;text-align:center;line-height:150%'><span style='font-size:9.0pt;line-height:150%;font-family:"Helvetica",sans-serif;color:#656565'><br><br>Want to change how you receive these emails?<br><br><o:p></o:p></span></p></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table></div></td></tr></table></div><p class=MsoNormal><img border=0 width=1 height=1 style='width:.0104in;height:.0104in' id="_x0000_i1025" src="https://naspcc.us17.list-manage.com/track/open.php?u=9154133f2e98aca1db87520cb&id=01bbf25c56&e=d1cc1ed898"><o:p></o:p></p><p class=MsoNormal><span class=DefaultFontHxMailStyle><o:p> </o:p></span></p></div></body></html>